{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:59:12Z","timestamp":1773673152891,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00409-4","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:50:49Z","timestamp":1765817449000},"page":"73-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor\/Patient Podcast)"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0706-8775","authenticated-orcid":false,"given":"Rick","family":"Bangs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"409_CR1","unstructured":"AUA. American Urological Association AUA Annual Meeting. Maryland. American Urological Association (AUA). 2025. https:\/\/www.auanet.org\/AUA2025. Accessed 6 Nov 2025."},{"key":"409_CR2","unstructured":"Moffitt. Moffitt Cancer Center, Florida. https:\/\/www.moffitt.org\/. Accessed 6 Nov 2025."},{"key":"409_CR3","unstructured":"BCAN. Bladder cancer advocacy network: empowering better todays & more tomorrows. Maryland. Bladder Cancer Advocacy Network (BCAN). 2025. https:\/\/bcan.org\/. Accessed 6 Nov 2025."},{"issue":"5S","key":"409_CR4","volume":"213","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles T, Bedke J, et al. Sasanlimab in combination with bacillus Calmette-Guerin improves event-free survival versus bacillus Calmette-Guerin as standard of care in high-risk non- muscle-invasive bladder cancer: phase\u00a03 CREST study results. J Urol. 2025;213(5S):e1001.","journal-title":"J Urol"},{"issue":"5S2","key":"409_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.02","volume":"213","author":"MD Tyson","year":"2025","unstructured":"Tyson MD, Uchio EM, Nam J-K, et al. Final results: BOND-003 cohort C\u2014phase\u00a03, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. J Urol. 2025;213(5S2):e1.","journal-title":"J Urol"},{"issue":"5S2","key":"409_CR6","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1097\/01.JU.0001111604.90306.91.03","volume":"213","author":"JM Jacob","year":"2025","unstructured":"Jacob JM, Guerrero-Ramos F, Necchi A, et al. TAR-200 monotherapy in patients with bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SUNRISE-1. J Urol. 2025;213(5S2):e2\u20133.","journal-title":"J Urol"},{"issue":"5S2","key":"409_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.04","volume":"213","author":"F Guerrero-Ramos","year":"2025","unstructured":"Guerrero-Ramos F, Jacob JM, van der Heijden MS, et al. TAR-200 monotherapy in patients with bacillus Calmette-Guerin-unresponsive papillary disease-only high-risk non-muscle-invasive bladder cancer: first results from cohort 4 of SUNRISE-1. J Urol. 2025;213(5S2):e3.","journal-title":"J Urol"},{"issue":"5S2","key":"409_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001111604.90306.91.05","volume":"213","author":"JL Gore","year":"2025","unstructured":"Gore JL, Wolff EM, Nash MG, et al. Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: results from the comparison of intravesical therapy and surgery as tre catamount options (CISTO) study. J Urol. 2025;213(5S2):e3.","journal-title":"J Urol"},{"key":"409_CR9","unstructured":"US Food and Drug Administration. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer. Accessed 28 Oct 2025"},{"key":"409_CR10","unstructured":"US Food and Drug Administration. FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gemcitabine-intravesical-system-non-muscle-invasive-bladder-cancer. Accessed 28 Oct 2025"},{"key":"409_CR11","unstructured":"Patient-Centered Outcomes Research Institute (PCORI). Patient-Centered Outcomes Research Institute, Washington. https:\/\/www.pcori.org\/. Accessed 6 Nov 2025"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00409-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00409-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00409-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:44:15Z","timestamp":1773668655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00409-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00409-4","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rick Bangs: consulting fees and honoraria from AstraZeneca, Astellas, Gilead, Johnson and Johnson, Pfizer and travel support from AstraZeneca, Astellas, Gilead, Pfizer; Roger Li: grant funding from Predicine Inc, Veracyte CG Oncology, and Valar Labs, has received consulting fees from BMS, UroGen, Lucene, Merck, CG Oncology, and Thericon, has received support for travel from CG Oncology, and has stock in Crispr Therapeutics, Illumina, Eli Lily, and Guardant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This podcast article is based on data presented at AUA 2025 and does not contain any new studies with human participants or animals performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}